Consistently with these observations, the enhanced inhibition of HIF1α by combination treatment was observed in other colorectal cancer cells with different p53 status (Fig. 2D) (i.e. HT29: p53G273A; DLD1: p53C241T, SW480: p53G273A&C309T; RKO: p53wild-type). This evidence concerns the gene TP53 and colorectal cancer.